Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

NIDA studies TRV-734 in phase II for opioid use disorder

May 31, 2021

FDA clears IND for Lyndra's LYN-014 for weekly treatment of opioid use disorder

May 7, 2021

FDA approves Kloxxado for opioid overdose

May 4, 2021

Cybin targets IND filing for CYB-003 for alcohol use disorder by year-end

April 27, 2021

InterveXion reports phase II data on IXT-m200 in methamphetamine use disorder

April 20, 2021

FDA approves new expanded indication for Anavip

April 7, 2021

First subjects dosed in study comparing nasal nalmefene with nasal naloxone

April 6, 2021

Primary safety endpoint met in phase Ib/II study of BXCL-501 to treat opioid withdrawal symptoms

April 1, 2021

Brain cell alcohol metabolism affects behavior, addiction

March 25, 2021

DemeRx receives approval for phase I/II study of ibogaine in the U.K.

March 11, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 21, 2025.
Makary’s vision for slimmed-down US FDA somewhat reassuring
BioWorld
Nearly three weeks into the job, U.S. FDA Commissioner Marty Makary provided a comprehensive overview of his vision for the much-reduced agency, even as he’s...
Dupixent bounces back in treating hives with FDA approval
BioWorld
The U.S. FDA issued a complete response letter in October 2023 for Dupixent (dupilumab) in treating chronic hives but has now approved the monoclonal antibody for...
Ouch! Tariffs hit med tech harder than expected
BioWorld MedTech
First quarter earnings reports from Johnson & Johnson and Abbott Laboratories provided some surprising insights into the likely hit med-tech companies will...